Gradient Capital Advisors LLC Purchases New Stake in Orthofix Medical Inc. $OFIX

Key Points

• Gradient Capital Advisors LLC acquired a new position in Orthofix Medical Inc., buying 20,000 shares valued at approximately $223,000, representing 0.05% ownership in the company.
• Orthofix Medical's stock rating was upgraded by Wall Street Zen from "sell" to "hold," with an overall average rating of "Moderate Buy" and a target price of $21.75.
• Despite a revenue of $203.12 million, Orthofix Medical reported a loss per share of $0.36 for its last quarter, missing the consensus estimate by $0.40.

Gradient Capital Advisors LLC bought a new position in Orthofix Medical Inc. (NASDAQ:OFIX - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 20,000 shares of the medical device company's stock, valued at approximately $223,000. Gradient Capital Advisors LLC owned 0.05% of Orthofix Medical at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in OFIX. Bank of America Corp DE boosted its stake in Orthofix Medical by 14.0% during the fourth quarter. Bank of America Corp DE now owns 48,608 shares of the medical device company's stock valued at $849,000 after buying an additional 5,966 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Orthofix Medical by 4.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,348 shares of the medical device company's stock valued at $338,000 after acquiring an additional 836 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Orthofix Medical by 14.0% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 71,371 shares of the medical device company's stock valued at $1,246,000 after buying an additional 8,772 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Orthofix Medical by 1,585.1% during the 1st quarter. GAMMA Investing LLC now owns 22,867 shares of the medical device company's stock worth $373,000 after purchasing an additional 21,510 shares in the last quarter. Finally, Assenagon Asset Management S.A. grew its holdings in shares of Orthofix Medical by 421.1% during the 1st quarter. Assenagon Asset Management S.A. now owns 72,226 shares of the medical device company's stock worth $1,178,000 after purchasing an additional 58,366 shares in the last quarter. 89.76% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts recently commented on OFIX shares. Wall Street Zen raised Orthofix Medical from a "sell" rating to a "hold" rating in a research note on Saturday, August 9th. Barrington Research reaffirmed an "outperform" rating and issued a $17.00 price target on shares of Orthofix Medical in a research note on Tuesday. Finally, JMP Securities reaffirmed a "market perform" rating on shares of Orthofix Medical in a research note on Friday, June 6th. Four investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $21.75.

Orthofix Medical Stock Down 0.6%

NASDAQ:OFIX opened at $14.29 on Friday. Orthofix Medical Inc. has a 1 year low of $10.24 and a 1 year high of $20.73. The company has a current ratio of 2.67, a quick ratio of 1.50 and a debt-to-equity ratio of 0.38. The stock has a market cap of $564.31 million, a price-to-earnings ratio of -4.51 and a beta of 0.86. The stock has a 50-day moving average price of $13.66 and a two-hundred day moving average price of $13.10.

Orthofix Medical (NASDAQ:OFIX - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The medical device company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.40). Orthofix Medical had a negative return on equity of 25.43% and a negative net margin of 15.29%.The firm had revenue of $203.12 million for the quarter, compared to analyst estimates of $196.89 million. Orthofix Medical has set its FY 2025 guidance at EPS. As a group, equities analysts expect that Orthofix Medical Inc. will post -2.81 earnings per share for the current year.

About Orthofix Medical

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.